Home › Pancreatic Cancer › NCT04616131
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Biopsy or cytology proven adenocarcinoma of the pancreas * No clinical evidence of metastatic disease on imaging * Age 18 or older * Receiving chemotherapy for non-metastatic pancreatic cancer Exclusion Criteria: * Biopsy proven metastatic disease
About the study
For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.
Sponsor: Northwestern University · Participants: 500 · Started: Oct 1, 2020
Contact the study team
- Study Coordinator · Phone: 3126951301
- Donald Smith, MS · Phone: 630-352-5360
Official record on ClinicalTrials.gov — NCT04616131
Locations in the U.S.
| Illinois | Northwestern Medicine Cancer Center Kishwaukee, DeKalb Northwestern Medicine Cancer Center Delnor, Geneva Northwestern Medicine Cancer Center Warrenville, Warrenville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.